Phase 1 Trial of a Therapeutic Anti–Yellow Fever Virus Human Antibody

Phase 1 Trial of a Therapeutic Anti–Yellow Fever Virus Human Antibody

A phase 1a–1b trial of TY014, an IgG1 anti–yellow fever virus monoclonal antibody, did not identify worrisome safety signals. Ten participants were randomly assigned to receive TY014 or placebo 24 hours after live yellow fever vaccination (YF17D-204). YF17D-204 viremia was detectable in no participa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2020-07, Vol.383 (5), p.452-459
Hauptverfasser: Low, Jenny G, Ng, Justin H.J, Ong, Eugenia Z, Kalimuddin, Shirin, Wijaya, Limin, Chan, Yvonne F.Z, Ng, Dorothy H.L, Tan, Hwee-Cheng, Baglody, Anjali, Chionh, Yok-Hian, Lee, Debbie C.P, Budigi, Yadunanda, Sasisekharan, Ram, Ooi, Eng-Eong
Format: Artikel
Sprache:eng
Schlagworte:
Body weight
Clinical trials
Data collection
Fever
Gene expression
Health sciences
Immunoglobulin G
Infections
Licenses
Monoclonal antibodies
Pharmacokinetics
Safety
Vaccines
Viremia
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A phase 1a–1b trial of TY014, an IgG1 anti–yellow fever virus monoclonal antibody, did not identify worrisome safety signals. Ten participants were randomly assigned to receive TY014 or placebo 24 hours after live yellow fever vaccination (YF17D-204). YF17D-204 viremia was detectable in no participants in the TY014 group and in four in the placebo group, providing preliminary evidence of potential efficacy.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2000226